Registration for International Lung Cancer Summit 2026 is now open. Join co-chairs @peters_solange and @Alfdoc2 on the ILCS to discuss how the latest trial data impacts everyday clinical decisions. This is your opportunity to connect with colleagues and debate real-world treatment strategies for advanced NSCLC and SCLC. 🗓️ Friday, November 13ᵗʰ, 2026 📍 Lausanne, Switzerland & Live Online Secure your spot here ⬇️ lungsummit.org/#ILCS

Register now for our ETOP Live Webinar: Highlights of AACR and ASCO 2026, taking place Wednesday, 1 July 2026, 13:00 - 14:15h CET. register.gotowebinar.com/#re…

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers - Final results (full access link below) thanks to all esp the patients involved in the 1st NCI rare tumor IO basket study! sciencedirect.com/science/ar…

📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer 👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A) 👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B). 👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C) 👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D) ⚡ 💡 Largest #EGFR mutation landscape in a Western population. ⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC. ⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.

#iTOX @GustaveRoussy Thanks #AurelienMarabelle for the invitation to present on long-term ICI tox, key priorities: - collect nuanced irAE data beyond clinical trial followup - time tox, financial tox, HRQOL - balancing tox response: "impact" @CancerCentreIre @OncoAlert #LCSM

How should we structure future discussions to better address shifting paradigms in thoracic oncology? For the 8th consecutive year, @peters_solange and @Alfdoc2 will co-chair the ILCS 2026. Bringing decades of clinical expertise from @OncoUNILCHUV & @hug_ge, they will guide the discussion on the most critical clinical developments and treatment algorithms in NSCLC and SCLC. Join them live on 13ᵗʰ November and get registered ⬇️ lungsummit.org/#ILCS

Registration for International Lung Cancer Summit 2026 is now open. Join co-chairs @peters_solange and @Alfdoc2 on the ILCS to discuss how the latest trial data impacts everyday clinical decisions. This is your opportunity to connect with colleagues and debate real-world treatment strategies for advanced NSCLC and SCLC. 🗓️ Friday, November 13ᵗʰ, 2026 📍 Lausanne, Switzerland & Live Online Secure your spot here ⬇️ lungsummit.org/#ILCS

‼️‼️#Tarlatamab Keeps delivering. 🔥🚨@OncoAlert Hot off the press. Just presented @ASCO #ASCO26 by Dr. @g_mountzios ⭐️#PostHoc Analysis Results of #Intracranial🧠#Efficacy of: ❇️#Tarlatamab 🆚 #Chemotherapy in #2nd line treatment for #SmallCell #LungCancer in the #DeLLphi304 Trial. ‼️‼️#Exciting & #Promising Results: ✅⬆️CNS #mPFS 6.5 vs 4.2 m (HR 0.40) ✅⬆️CNS #CR: 15% vs 5% ✅⬆️CNS shrinkage ≥30%: 56% vs 38% ✅⬆️#mOS in pts with #BrainMets: 13.9 vs 6.8 m

🔔 Both ES-SCLC treatments flagged at CHMP in March have now received full European Commission marketing authorization, moving from positive opinion to formal EU approval. These additions are clinically meaningful in a disease that remains aggressive, relapses early, and has historically offered patients few options after first-line platinum-based chemotherapy. ⭕ Tarlatamab by @Amgen This is the first DLL3-targeting bispecific T-cell engager authorized for SCLC in the EU. Approved now as monotherapy for adults with ES-SCLC requiring systemic therapy after progression on or after first-line platinum-based chemotherapy. In the Phase 3 DeLLphi-304 trial, tarlatamab reduced the risk of death by 40% versus standard-of-care chemotherapy (median OS 13.6 vs 8.3 months). CRS and ICANS are recognized risks, so step-up dosing and monitoring in an appropriate care setting are required. ⭕ Lurbinectedin by @PhrmMar Approved in combination with atezolizumab (@Roche) as first-line maintenance for adults with ES-SCLC whose disease has not progressed after induction with atezolizumab, carboplatin and etoposide. In the Phase 3 IMforte trial, the combination reduced the risk of progression or death by 46% and the risk of death by 27% versus atezolizumab alone (median OS 13.2 vs 10.6 months; median PFS 5.4 vs 2.1 months). Together, these approvals address two distinct points in the ES-SCLC treatment pathway: first-line maintenance and the relapsed/progressed setting – gradually building out a new therapeutic landscape.

💥 Ivonescimab overperforms tislelizumab in combination with chemotherapy in squamous lung cancer in Chinese population. Better OS regardless of PD-L1 expression. While global confirmatory trial is underway, these results may have immediate implications. #ASCO26 #LCSM

An exquisite educational session at #ASCO26 on present &future of #SCLC , with amazing hosts @RManochakian @NReguart Fiona Johnson 👏 State of the art presentations by global experts in a fully packed room Don’t miss their ASCO Educ book 📕 chapter on SCLC coming out 2nd June!

First positive adjuvant pIII study wth selpercatinib in stage IB–IIIA RET-positive NSCLC: LIBRETTO-432. Impressive results!, now in #NEJM. Nicely discussed @christine_lovly TKI duration, MRD, screening, and broader biomarker testing in early-stage #ASCO26 #NSCLC #RETfusion

Digesting all the new lung cancer updates at #ASCO26 with lung cancer experts and friends from around the world! @HyeinJeon_MD @ipreeshagul @Piuchagarrido @EnriquetaFelip @isla_dolores @jennifermarksmd @TurgemanIlit @benlevylungdoc @NReguart @DrSanjayPopat @JairBar4

The #WNTD 2026 theme, “Unmasking the appeal: Countering nicotine and tobacco addictions” highlights the industry strategies used to bypass established regulations. Policy makers and healthcare workers must look beyond traditional tobacco to address how new products drive dependence, ensuring our advocacy focuses on systemic accountability rather than patient stigma.

What does it take for DLL3 expression to become a predictive biomarker for T-cell engagers in small cell lung cancer? At our Year in Review roundtable, @peters_solange and @charlesrudin discussed the limits of current data: expression is required for binding, but the level does not predict efficacy. ~15% of SCLC tumors show very low levels of DLL3 and are often associated with the transcription factor POU2F3. Perhaps such biomarkers may help in future decision making. Watch the full discussion ⬇️ lungsummit.org/sclc/

Could antibody-drug conjugates redefine second line therapy in small cell lung cancer? At ILCS 2025, @NReguart reviewed B7-H3 directed ADCs reaching response rates of 41-64% in early phase trials, well above second line chemotherapy and tarlatamab. Phase III trials against topotecan are ongoing, with extensions into first line and limited stage. Watch the full discussion to learn more about ADCs in both SCLC and NSCLC ⬇️ lungsummit.org/adcs/

At our Year in Review roundtable, @MartinReck2 and @charlesrudin discussed whether consolidation therapy with DLL3 bispecific T-cell engagers could extend into limited stage NSCLC, alongside a potential role in the perioperative management of very early SCLC. Both emphasized that such small patient populations still deserve careful study when the goal is improving long term cure rates. Could these indications soon be ready to revisit? Watch the full discussion with @peters_solange ⬇️ lungsummit.org/sclc/

What is the role of tissue biopsy at progression in EGFR NSCLC, when liquid biopsy may be an alternative? At ILCS 2025, @peters_solange asked @TommyJohn00. His view: tissue is essential when accessible. More tissue biopsies have revealed more small cell transformation than expected, often without phenotypic clues, and liquid biopsy will miss it. Watch the full discussion to learn how rebiopsy practice is evolving after progression ⬇️ lungsummit.org/targeted-ther…

Can targeted rechallenge restore response to immunotherapy in heavily pre-treated lung cancer? At ILCS 2025, @MdCurioni shared two strategies. SAKK 17/18 combined PD-(L)1 inhibition with a steroid free gemcitabine, reaching ORR 31% and DCR 53%. RECLAIM added radiotherapy at up to four sites to dual checkpoint blockade after anti-PD-1 failure, with ORR 29%. Watch the full discussion to learn more about strategies in 2L and beyond ⬇️ lungsummit.org/metastatic-ns…